兔VX2肝癌TACE实验方法改良、药物应用及评价
|
摘要
目的：改进兔VX2肝癌模型介入治疗的实验方法，分析兔VX2肝肿瘤的影像学表现。
方法：开腹种植VX2瘤块于兔肝左叶，建立VX2肝肿瘤模型兔15只。2周后行CT及彩超检查证实接种成功。应用显微外科手术临时阻断肝总动脉血流，经胃十二指肠动脉留置导管行介入治疗，再恢复肝动脉血流，术后导管埋置于皮下。用多层螺旋CT(MSCT)、彩色超声和数字剪影血管造影(DSA)对兔VX2肝肿瘤行影像学评价。
结果：经胃十二指肠动脉留置导管操作成功11只，麻醉过量致死及术中大出血死亡各1只，另2只因解剖变异未做插管。MSCT平扫兔VX2肝肿瘤表现为低密度结节影：彩超上瘤灶为低回声光团，肿瘤周边及内部可见较丰富血流信号；DSA图像示VX2瘤灶于动脉期呈结节状肿瘤染色，以周边染色为主。
结论：经胃十二指肠动脉留置导管对兔VX2肝癌行术中介入治疗，可实现超选择血管介入治疗，对肝脏血流动力学影响较小，便于术后观察，实验人员可完全避免放射辐射，但对实验条件和实验技术有一定要求。
目的：研究经导管动脉注射羟基磷灰石纳米微粒(nHAP)对兔肝VX2肿瘤的治疗作用，并了解碘油和nHAP混合物在主要脏器的分布和影响。
方法：将45只成功接种肝VX2肿瘤的模型兔随机分成3组，每组15只，用显微外科手术临时阻断肝总动脉血流，经胃十二指肠动脉插管分别给药行介入治疗，术毕结扎胃十二指肠动脉。A组为生理盐水组(对照组)，注射生理盐水0．5～1．0ml；B组为碘油组(疗效对比组)，注射超液化碘油0．5～1．0ml；C组为nHAP组，注入0．5％nHAP 0．5～1．0ml。3组实验动物分别于治疗前、治疗后7、14天行多层螺旋CT(MSCT)肝脏扫描，测量肿瘤的大小，并计算肿瘤生长率。治疗前、治疗后第1、7天测血清天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)两项肝酶指标；并记录各组术后生存天数。另取6只肝VX2肿瘤的模型兔按C组方法灌注nHAP和碘油的混合物0．5～1．0ml后，定期处死(术后1h和术后24h各处死3只)，通过病理切片HE染色和透射电镜分析了解碘油-nHAP混合物对主要脏器的影响和分布情况。
结果：术后7、14天，A组动物的肿瘤生长率分别为350±116％和1098±337％、B组为234±18％和730±32％，C组为233±15％和723±30％。B、C两组与A组相比差异有显著性(P＜0．05)，B组与C组之间无明显差异(P＞0．05)。术前各组血清AST、ALT水平差异无统计学意义(P＞0．05)，术后1天，A、B、C组血清AST、ALT均升高，B、C组上升幅度稍高，但与A组相比差异无统计学意义(P＞0．05)。术后7天，各组AST、ALT均降至正常范围。A、B、C组瘤兔的生存期分别为38．0±5．4d、54．0±8．1d、56．0±8．2d，B、C两组与A相比生存期明显延长(P＜0．05)。光镜下HE染色见肝内肿瘤组织表现为癌巢和坏死结构，癌旁肝组织、心、肾、肺、脾等均无异常。透射电镜显示术后1h和24h兔肝肿瘤组织中均可见nHAP沉积，而其他脏器内均未见nHAP分布。
结论：经动脉灌注nHAP治疗兔肝VX2肿瘤能有效抑制肿瘤生长，延长瘤兔的生存期，而无明显肝功能损害；经动脉灌注碘油和nHAP的混合物后，药物主要分布于肿瘤组织，而其他重要脏器内未见nHAP分布，亦未见相关并发症发生。
目的：通过影像学和病理学评价经胃十二指肠动脉注射5-FU缓释微球对兔VX2肝肿瘤的治疗作用。
方法：将成功接种肝VX2肿瘤的模型兔随机分成4组，每组10只，用显微外科手术临时阻断肝总动脉血流，经胃十二指肠动脉插管至肝固有动脉起始部给药行介入治疗，术毕结扎胃十二指肠动脉。A组(生理盐水对照组)，注射生理盐水0．5～1ml：B组(碘佛醇对照组)，注射碘佛醇0．5～1ml；C组为碘油组(疗效对比组)，注射超液化碘油0．5～1．0ml；D组为5-FU缓释微球组(实验组)，注射5-FU缓释微球10mg和碘佛醇1ml的混合溶液。4组实验动物于治疗1周后观察肿瘤的生长情况，坏死程度，并采用原位末端标记法(TUNEL)检测肿瘤细胞凋亡指数(AI)。
结果：治疗1周后D组(5-FU缓释微球组)肿瘤生长受到抑制，肿瘤生长率低于A组(生理盐水对照组)及B组(碘佛醇对照组)(P＜0．05)，与C组(碘油组)相比无显著性差异(P＞0．05)。4组肿瘤均有不同程度的坏死，D组(5-FU缓释微球组)肿瘤坏死率明显高于A组(生理盐水对照组)和B组(碘佛醇对照组)(P＜0．05)。A组(生理盐水对照组)、B组(碘佛醇对照组)和D组(5-FU缓释微球组)肿瘤细胞凋亡指数分别为1．69±0．18、1．75+0．27和8．03±0．63，5-FU缓释微球组与两对照组相比差异有统计学意义(P＜0．05)。
结论：5-FU缓释微球经动脉灌注可抑制肝肿瘤生长，诱导肿瘤细胞凋亡，促进肿瘤坏死，是一种有效的化疗栓塞剂。
目的：研究经胃十二指肠动脉灌注重组改构肿瘤坏死因子(TNF)对兔VX2肝肿瘤的疗效。
方法：将成功接种肝VX2肿瘤的模型兔随机分成3组，每组10只，用显微外科手术临时阻断肝总动脉血流，经胃十二指肠动脉插管至肝固有动脉起始部，行介入治疗，术毕结扎胃十二指肠动脉，重新开放肝总动脉血流。A组(空白对照组)，注射生理盐水0．5～1ml：B组为碘油组(疗效对比组)，注射超液化碘油0．5～1．0ml；C组为重组改构TNF组(实验组)，注射重组改构TNF 2．5万U和生理盐水的混合液0．5～1．0ml。3组实验动物于治疗1周后多层螺旋CT(MSCT)观察肿瘤的生长情况。以病理学方法评价肿瘤坏死程度，采用原位末端标记法(TUNEL)检测肿瘤细胞凋亡指数(AI)，并通过免疫组化的方法检测介入治疗后生理盐水组、碘油组和TNF组肿瘤组织的血管内皮生长因子(VEGF)表达程度和微血管密度(MVD)。
结果：术后1周后C组(TNF组)肿瘤生长受到抑制，肿瘤生长率低于A组(生理盐水对照组)(P＜0．05)，与B组(碘油组)无显著差异(P＞0．05)。3组肿瘤均有不同程度的坏死，C组(TNF组)和B组(碘油组)肿瘤坏死率明显高于A组(P＜0．05)。A组(空白对照组)和C组(TNF组)肿瘤细胞凋亡指数分别为1．69±0．18和7．26±0．45，两者相比差异有统计学意义(P＜0．05)。相对生理盐水组，介入治疗后TNF组残余肿瘤组织中的VEGF表达和MVD均有所下降．
结论：重组改构TNF经动脉灌注可抑制VX2肿瘤生长，促进肿瘤细胞凋亡和肿瘤坏死，并可抑制肿瘤血管新生，是一种有效的局部化疗手段。
PartⅠImprovement of Transarterial Embolization of RabbitModels with VX2 Hepatoma and Imaging Evaluation
Objective:To improve intra-arterial adminstration of rabbit models with VX2hepatoma and evaluate the manifestations of the VX2 hepatomas on mutislice spiralcomputed tomography (MSCT),colorful ultrasonography and digital subtractionangiography (DSA).
Methods:Fifteen New Zealand white rabbits were inoculated with fragment of VX2hepatomas into the left lobe of liver.After 2 weeks,all the rabbits were proved withliver neoplasms by MSCT scanning and colorful ultrasonography.During the openlaparotomy,common hepatic artery was ligated temporarily before transarterialembolization (TAE),and a catheter was inserted via gastroduodenal artery monitoredunder a microscope and detained in rabbit's abdomen.TAE was performed on therabbits.And then let common hepatic artery reperfuse.MSCT scanning,colorfulultrasonography and DSA were performed to describe the features of rabbit hepaticneoplasmas.
Results:TAE was successfully performed in 11 rabbits.One rabbit died foroverdosage of anesthesia.Another rabbit died for massive bleeding during thesurgeon.Artery anatomy mutations existed in two rabbits,so catheterization wasquitted.VX2 hepatomas appeared as low density nodule-like shadow on MSCTimagings,and showed low echoes,higher blood flow signals on colorfulultrasonography.Trans-gastroduodenal artery angiography showed that VX2hepatomas had nodule-like tumor stain mainly around the tumor in arterial phase.
Conclusion:Superselective embolization can be performed by detained catheter viagastroduodenal artery during the open laparotomy and has little impact on hepatichemodynamics.DSA can be easily used to follow up by the detained catheter.Furthermore,operators can completely avoid radiation,but the requirements of condition and technology are higher than usual.
PartⅡMSCT Effect study and Safety evaluation of TransarterialEmbolization Therapy with Nan Hydroxyapatite Particle on Rabbitswith VX2 Hepatoma
Objective:To study the effects of nan hydroxyapatite particle (nHAP) on rabbits withVX2 hepatoma,and analyze distribution and impact of nHAP and lipidol mixture inmain organs.
Methods:45 rabbits implanted liver VX2 tumors were randomly divided into 3groups.Each group had 15 rabbits.All the rabbits were proved with liver neoplasmasby mutislice spiral computed tomography (MSCT).During the open laparotomy,common hepatic artery was ligated temporarily,and then a catheter was inserted viagastroduodenal artery under a microscope.Administration was performed by thecatheter on the rabbits.Group A (control group) was administrated with 0.5 to 1.0 mlsaline;Group B (lipiodol group) was administrated with 0.5 to 1.0ml lipiodol;GroupC (nHAP group) was administrated with 0.5 to 1.0ml 0.5% nHAP.MSCT scan wasperformed to measure tumor volume on the 7th day and 14th day after theintervention.Serum levels of AST and ALT were measured on the 1st day and 7th dayafter the intervention thrapy.The survivals of VX2 rabbits were also descriped.Another 6 rabbits with VX2 hepatomas were administrated with 0.5 to 1.0ml mixtureof nHAP and lipidol,and put them to death at regular intervals (1 hour and 24 hoursafter intervention).Distribution and impact of lipidol and nHAP mixture in vitalorgans were analyzed by pathological section and transmission electron microscope.
Results:The tumor growth rates of group B and C on the 7th day and 14th day aftertreatment were lower than those of control group (P＜0.05).The tumor growth ratesbetween group B and C on the 7th day and 14th day after treatment were similar(P＞0.05).The life span of both group B and group C were longer than that of thecontrol group (P＜0.05).The serum levels of AST and ALT in all three groups werelittle higher than that of before the intervention (P＞0.05).The serum levels of AST or ALT in all groups became normal level on the 7th day after the intervention thrapy.Pathological sections showed cancer nesst and necrosis structures in VX2 hepatoma,and no abnormal structures in other organs.Under transmission electron microscope,distribution of nHAP and lipidol was found only in tumor tissues at both 1 hour and24 hours after intervention,but could't found in other organs.
Conclusion:The interventional therapy with nHAP has signifigant inhibitory effecton rabbits with VX2 hepatoma,and can prolong the rabbits life span.There are noobvious liver toxicity by using the interventional therapy.Lipidol and nHAP mixturealways distribute in tumor tissues after transarterial intervention,and no nHAP can befound in other vital organs.There are no relative complications after nHAPintervention thrapy.
PartⅢExperimental Study and Effect Evaluation ofTransarterial Chemoebolizasion with 5-FU Sustained-ReleaseMicrosphere on Rabbits with VX2 Hepatoma
Objective:To study the therapeutic efficacy of 5-FU sustained-release microspherechemoembolization through gastroduodenal artery on rabbits with VX2 hepatoma byradiology and pathology methods.
Methods:40 rabbits implanted liver VX2 tumors were randomly divided into 4groups.Each group had 10 rabbits.All the rabbits were proved with liver neoplasmasby multislice spiral computed tomograpy (MSCT).During the open laparotomy,common hepatic artery was ligated temporarily,then a catheter was inserted viagastroduodenal artery under a microscope and administration was performed throughthe catheter.We ligated gastroduodenal artery and let common hepatic artery repefuseafter administration.Group A (blank control group) was administrated with 0.5 to1.0 ml saline;Group B (contrast agent group) was administrated with 0.5 to 1.0mlioversol injection;Group C (lipiodol group) was administrated with 0.5 to 1.0mllipiodol;Group D (5-FU sustained-release microsphere group) was administratedwith mixture of 10mg 5-FU sustained- release microsphere and lml ioversol.MSCTscan was performed to measure tumor volume on the 7th day after treatment.Thetumor growth rates,necrosis rates and the tumor apoptotic index (AI) were examinedand compared.
Results:One week after treatment,in the 5-FU sustained-release microsphere group(group D) the tumor was significantly inhibited,tumor growth rate was lower than thegroup A and group B (P＜0.05),and was similar to group C (P＞0.05).The tumornecrosis rates of group D was singnificantly higher than those of group A and B(P＜0.05).The tumor AIs were 1.69±0.18 (group A),1.75+0.27 (group B),8.03+0.63 (group D),respectively (P＜0.05).AI of group D was singnificantly higher than thatof group A and B.
Conclusion:5-FU sustained-release microsphere infusion through artery to liver caninhibit tumor growth,induce the apoptosis and aggravate the tumor necrosis.It is aneffective chemoembolization agent.
PartⅣExperimental Study and Effect Analysis of TransarterialChemotherapy with Recombinant mutant TNF on Rabbits with VX2Hepatoma
Objective:To study the therapeutic efficacy of recombinant mutant human tumornecrosis factor (TNF) chemotherapy through gastroduodenal artery on rabbits withVX2 hepatoma.
Methods:30 rabbits implanted liver VX2 hepatoma were randomly divided into 3groups.Each group had 10 rabbits.All the rabbits were proved with liver neoplasmasby multislice spiral computed tomograpy (MSCT).During the open laparotomy,commonhepatic artery was temporarily ligated,and then a catheter was inserted viagastroduodenal artery under a microscope and administration was performed throughthe catheter.We ligated gastroduodenal artery and let common hepatic artery repefuseafter administration.Group A (blank control group) was administrated with 0.5 to 1.0ml saline;Group B (lipiodol group) was administrated with 0.5 to 1.0ml lipiodol;Group C (recombined TNF group) was administrated with mixture of 2.5×10~4 IUrecombinant mutant TNF and 1ml saline.MSCT scan was performed to measuretumor volume on the 7th day after intervention.The tumor growth rates and necrosisrates were measured.Tumor apoptotic indexs examined by TUNEL were comparedbetween group A and C.VEGF expression and MVD of all groups were detected byimmunohistochemistry.
Results:One week after treatment,in the recombinant mutant TNF group (group C)the tumor was significantly inhibited,tumor growth rate was lower than the group A(P＜0.05),and was similar to group B (P＞0.05).Tumor necrosis of group A wassignificantly different from group B and C,and the necrosis rate of group B and Cwas higher than group A (P＜0.05).Tumor apoptotic indexs (AI) were 1.69±0.18 ingroup A and 7.26±0.45 in group C,and there was singnificant difference betweengroup A and group C (P＜0.05).Vascular endothelial growth factor (VEGF) expression and microvessel density (MVD) of group C were singnificantly decreased(P＜0.05).
Conclusion:Recombinant mutant human TNF chemotherapy through artery to livercan inhibit tumor growth,reduce vescular growth and induce apoptosis and/or tumornecrosis.Recombinant mutant human TNF is an effective chemotherapy agent forrabbits with VX2 hepatoma.
方法：开腹种植VX2瘤块于兔肝左叶，建立VX2肝肿瘤模型兔15只。2周后行CT及彩超检查证实接种成功。应用显微外科手术临时阻断肝总动脉血流，经胃十二指肠动脉留置导管行介入治疗，再恢复肝动脉血流，术后导管埋置于皮下。用多层螺旋CT(MSCT)、彩色超声和数字剪影血管造影(DSA)对兔VX2肝肿瘤行影像学评价。
结果：经胃十二指肠动脉留置导管操作成功11只，麻醉过量致死及术中大出血死亡各1只，另2只因解剖变异未做插管。MSCT平扫兔VX2肝肿瘤表现为低密度结节影：彩超上瘤灶为低回声光团，肿瘤周边及内部可见较丰富血流信号；DSA图像示VX2瘤灶于动脉期呈结节状肿瘤染色，以周边染色为主。
结论：经胃十二指肠动脉留置导管对兔VX2肝癌行术中介入治疗，可实现超选择血管介入治疗，对肝脏血流动力学影响较小，便于术后观察，实验人员可完全避免放射辐射，但对实验条件和实验技术有一定要求。
目的：研究经导管动脉注射羟基磷灰石纳米微粒(nHAP)对兔肝VX2肿瘤的治疗作用，并了解碘油和nHAP混合物在主要脏器的分布和影响。
方法：将45只成功接种肝VX2肿瘤的模型兔随机分成3组，每组15只，用显微外科手术临时阻断肝总动脉血流，经胃十二指肠动脉插管分别给药行介入治疗，术毕结扎胃十二指肠动脉。A组为生理盐水组(对照组)，注射生理盐水0．5～1．0ml；B组为碘油组(疗效对比组)，注射超液化碘油0．5～1．0ml；C组为nHAP组，注入0．5％nHAP 0．5～1．0ml。3组实验动物分别于治疗前、治疗后7、14天行多层螺旋CT(MSCT)肝脏扫描，测量肿瘤的大小，并计算肿瘤生长率。治疗前、治疗后第1、7天测血清天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)两项肝酶指标；并记录各组术后生存天数。另取6只肝VX2肿瘤的模型兔按C组方法灌注nHAP和碘油的混合物0．5～1．0ml后，定期处死(术后1h和术后24h各处死3只)，通过病理切片HE染色和透射电镜分析了解碘油-nHAP混合物对主要脏器的影响和分布情况。
结果：术后7、14天，A组动物的肿瘤生长率分别为350±116％和1098±337％、B组为234±18％和730±32％，C组为233±15％和723±30％。B、C两组与A组相比差异有显著性(P＜0．05)，B组与C组之间无明显差异(P＞0．05)。术前各组血清AST、ALT水平差异无统计学意义(P＞0．05)，术后1天，A、B、C组血清AST、ALT均升高，B、C组上升幅度稍高，但与A组相比差异无统计学意义(P＞0．05)。术后7天，各组AST、ALT均降至正常范围。A、B、C组瘤兔的生存期分别为38．0±5．4d、54．0±8．1d、56．0±8．2d，B、C两组与A相比生存期明显延长(P＜0．05)。光镜下HE染色见肝内肿瘤组织表现为癌巢和坏死结构，癌旁肝组织、心、肾、肺、脾等均无异常。透射电镜显示术后1h和24h兔肝肿瘤组织中均可见nHAP沉积，而其他脏器内均未见nHAP分布。
结论：经动脉灌注nHAP治疗兔肝VX2肿瘤能有效抑制肿瘤生长，延长瘤兔的生存期，而无明显肝功能损害；经动脉灌注碘油和nHAP的混合物后，药物主要分布于肿瘤组织，而其他重要脏器内未见nHAP分布，亦未见相关并发症发生。
目的：通过影像学和病理学评价经胃十二指肠动脉注射5-FU缓释微球对兔VX2肝肿瘤的治疗作用。
方法：将成功接种肝VX2肿瘤的模型兔随机分成4组，每组10只，用显微外科手术临时阻断肝总动脉血流，经胃十二指肠动脉插管至肝固有动脉起始部给药行介入治疗，术毕结扎胃十二指肠动脉。A组(生理盐水对照组)，注射生理盐水0．5～1ml：B组(碘佛醇对照组)，注射碘佛醇0．5～1ml；C组为碘油组(疗效对比组)，注射超液化碘油0．5～1．0ml；D组为5-FU缓释微球组(实验组)，注射5-FU缓释微球10mg和碘佛醇1ml的混合溶液。4组实验动物于治疗1周后观察肿瘤的生长情况，坏死程度，并采用原位末端标记法(TUNEL)检测肿瘤细胞凋亡指数(AI)。
结果：治疗1周后D组(5-FU缓释微球组)肿瘤生长受到抑制，肿瘤生长率低于A组(生理盐水对照组)及B组(碘佛醇对照组)(P＜0．05)，与C组(碘油组)相比无显著性差异(P＞0．05)。4组肿瘤均有不同程度的坏死，D组(5-FU缓释微球组)肿瘤坏死率明显高于A组(生理盐水对照组)和B组(碘佛醇对照组)(P＜0．05)。A组(生理盐水对照组)、B组(碘佛醇对照组)和D组(5-FU缓释微球组)肿瘤细胞凋亡指数分别为1．69±0．18、1．75+0．27和8．03±0．63，5-FU缓释微球组与两对照组相比差异有统计学意义(P＜0．05)。
结论：5-FU缓释微球经动脉灌注可抑制肝肿瘤生长，诱导肿瘤细胞凋亡，促进肿瘤坏死，是一种有效的化疗栓塞剂。
目的：研究经胃十二指肠动脉灌注重组改构肿瘤坏死因子(TNF)对兔VX2肝肿瘤的疗效。
方法：将成功接种肝VX2肿瘤的模型兔随机分成3组，每组10只，用显微外科手术临时阻断肝总动脉血流，经胃十二指肠动脉插管至肝固有动脉起始部，行介入治疗，术毕结扎胃十二指肠动脉，重新开放肝总动脉血流。A组(空白对照组)，注射生理盐水0．5～1ml：B组为碘油组(疗效对比组)，注射超液化碘油0．5～1．0ml；C组为重组改构TNF组(实验组)，注射重组改构TNF 2．5万U和生理盐水的混合液0．5～1．0ml。3组实验动物于治疗1周后多层螺旋CT(MSCT)观察肿瘤的生长情况。以病理学方法评价肿瘤坏死程度，采用原位末端标记法(TUNEL)检测肿瘤细胞凋亡指数(AI)，并通过免疫组化的方法检测介入治疗后生理盐水组、碘油组和TNF组肿瘤组织的血管内皮生长因子(VEGF)表达程度和微血管密度(MVD)。
结果：术后1周后C组(TNF组)肿瘤生长受到抑制，肿瘤生长率低于A组(生理盐水对照组)(P＜0．05)，与B组(碘油组)无显著差异(P＞0．05)。3组肿瘤均有不同程度的坏死，C组(TNF组)和B组(碘油组)肿瘤坏死率明显高于A组(P＜0．05)。A组(空白对照组)和C组(TNF组)肿瘤细胞凋亡指数分别为1．69±0．18和7．26±0．45，两者相比差异有统计学意义(P＜0．05)。相对生理盐水组，介入治疗后TNF组残余肿瘤组织中的VEGF表达和MVD均有所下降．
结论：重组改构TNF经动脉灌注可抑制VX2肿瘤生长，促进肿瘤细胞凋亡和肿瘤坏死，并可抑制肿瘤血管新生，是一种有效的局部化疗手段。
PartⅠImprovement of Transarterial Embolization of RabbitModels with VX2 Hepatoma and Imaging Evaluation
Objective:To improve intra-arterial adminstration of rabbit models with VX2hepatoma and evaluate the manifestations of the VX2 hepatomas on mutislice spiralcomputed tomography (MSCT),colorful ultrasonography and digital subtractionangiography (DSA).
Methods:Fifteen New Zealand white rabbits were inoculated with fragment of VX2hepatomas into the left lobe of liver.After 2 weeks,all the rabbits were proved withliver neoplasms by MSCT scanning and colorful ultrasonography.During the openlaparotomy,common hepatic artery was ligated temporarily before transarterialembolization (TAE),and a catheter was inserted via gastroduodenal artery monitoredunder a microscope and detained in rabbit's abdomen.TAE was performed on therabbits.And then let common hepatic artery reperfuse.MSCT scanning,colorfulultrasonography and DSA were performed to describe the features of rabbit hepaticneoplasmas.
Results:TAE was successfully performed in 11 rabbits.One rabbit died foroverdosage of anesthesia.Another rabbit died for massive bleeding during thesurgeon.Artery anatomy mutations existed in two rabbits,so catheterization wasquitted.VX2 hepatomas appeared as low density nodule-like shadow on MSCTimagings,and showed low echoes,higher blood flow signals on colorfulultrasonography.Trans-gastroduodenal artery angiography showed that VX2hepatomas had nodule-like tumor stain mainly around the tumor in arterial phase.
Conclusion:Superselective embolization can be performed by detained catheter viagastroduodenal artery during the open laparotomy and has little impact on hepatichemodynamics.DSA can be easily used to follow up by the detained catheter.Furthermore,operators can completely avoid radiation,but the requirements of condition and technology are higher than usual.
PartⅡMSCT Effect study and Safety evaluation of TransarterialEmbolization Therapy with Nan Hydroxyapatite Particle on Rabbitswith VX2 Hepatoma
Objective:To study the effects of nan hydroxyapatite particle (nHAP) on rabbits withVX2 hepatoma,and analyze distribution and impact of nHAP and lipidol mixture inmain organs.
Methods:45 rabbits implanted liver VX2 tumors were randomly divided into 3groups.Each group had 15 rabbits.All the rabbits were proved with liver neoplasmasby mutislice spiral computed tomography (MSCT).During the open laparotomy,common hepatic artery was ligated temporarily,and then a catheter was inserted viagastroduodenal artery under a microscope.Administration was performed by thecatheter on the rabbits.Group A (control group) was administrated with 0.5 to 1.0 mlsaline;Group B (lipiodol group) was administrated with 0.5 to 1.0ml lipiodol;GroupC (nHAP group) was administrated with 0.5 to 1.0ml 0.5% nHAP.MSCT scan wasperformed to measure tumor volume on the 7th day and 14th day after theintervention.Serum levels of AST and ALT were measured on the 1st day and 7th dayafter the intervention thrapy.The survivals of VX2 rabbits were also descriped.Another 6 rabbits with VX2 hepatomas were administrated with 0.5 to 1.0ml mixtureof nHAP and lipidol,and put them to death at regular intervals (1 hour and 24 hoursafter intervention).Distribution and impact of lipidol and nHAP mixture in vitalorgans were analyzed by pathological section and transmission electron microscope.
Results:The tumor growth rates of group B and C on the 7th day and 14th day aftertreatment were lower than those of control group (P＜0.05).The tumor growth ratesbetween group B and C on the 7th day and 14th day after treatment were similar(P＞0.05).The life span of both group B and group C were longer than that of thecontrol group (P＜0.05).The serum levels of AST and ALT in all three groups werelittle higher than that of before the intervention (P＞0.05).The serum levels of AST or ALT in all groups became normal level on the 7th day after the intervention thrapy.Pathological sections showed cancer nesst and necrosis structures in VX2 hepatoma,and no abnormal structures in other organs.Under transmission electron microscope,distribution of nHAP and lipidol was found only in tumor tissues at both 1 hour and24 hours after intervention,but could't found in other organs.
Conclusion:The interventional therapy with nHAP has signifigant inhibitory effecton rabbits with VX2 hepatoma,and can prolong the rabbits life span.There are noobvious liver toxicity by using the interventional therapy.Lipidol and nHAP mixturealways distribute in tumor tissues after transarterial intervention,and no nHAP can befound in other vital organs.There are no relative complications after nHAPintervention thrapy.
PartⅢExperimental Study and Effect Evaluation ofTransarterial Chemoebolizasion with 5-FU Sustained-ReleaseMicrosphere on Rabbits with VX2 Hepatoma
Objective:To study the therapeutic efficacy of 5-FU sustained-release microspherechemoembolization through gastroduodenal artery on rabbits with VX2 hepatoma byradiology and pathology methods.
Methods:40 rabbits implanted liver VX2 tumors were randomly divided into 4groups.Each group had 10 rabbits.All the rabbits were proved with liver neoplasmasby multislice spiral computed tomograpy (MSCT).During the open laparotomy,common hepatic artery was ligated temporarily,then a catheter was inserted viagastroduodenal artery under a microscope and administration was performed throughthe catheter.We ligated gastroduodenal artery and let common hepatic artery repefuseafter administration.Group A (blank control group) was administrated with 0.5 to1.0 ml saline;Group B (contrast agent group) was administrated with 0.5 to 1.0mlioversol injection;Group C (lipiodol group) was administrated with 0.5 to 1.0mllipiodol;Group D (5-FU sustained-release microsphere group) was administratedwith mixture of 10mg 5-FU sustained- release microsphere and lml ioversol.MSCTscan was performed to measure tumor volume on the 7th day after treatment.Thetumor growth rates,necrosis rates and the tumor apoptotic index (AI) were examinedand compared.
Results:One week after treatment,in the 5-FU sustained-release microsphere group(group D) the tumor was significantly inhibited,tumor growth rate was lower than thegroup A and group B (P＜0.05),and was similar to group C (P＞0.05).The tumornecrosis rates of group D was singnificantly higher than those of group A and B(P＜0.05).The tumor AIs were 1.69±0.18 (group A),1.75+0.27 (group B),8.03+0.63 (group D),respectively (P＜0.05).AI of group D was singnificantly higher than thatof group A and B.
Conclusion:5-FU sustained-release microsphere infusion through artery to liver caninhibit tumor growth,induce the apoptosis and aggravate the tumor necrosis.It is aneffective chemoembolization agent.
PartⅣExperimental Study and Effect Analysis of TransarterialChemotherapy with Recombinant mutant TNF on Rabbits with VX2Hepatoma
Objective:To study the therapeutic efficacy of recombinant mutant human tumornecrosis factor (TNF) chemotherapy through gastroduodenal artery on rabbits withVX2 hepatoma.
Methods:30 rabbits implanted liver VX2 hepatoma were randomly divided into 3groups.Each group had 10 rabbits.All the rabbits were proved with liver neoplasmasby multislice spiral computed tomograpy (MSCT).During the open laparotomy,commonhepatic artery was temporarily ligated,and then a catheter was inserted viagastroduodenal artery under a microscope and administration was performed throughthe catheter.We ligated gastroduodenal artery and let common hepatic artery repefuseafter administration.Group A (blank control group) was administrated with 0.5 to 1.0ml saline;Group B (lipiodol group) was administrated with 0.5 to 1.0ml lipiodol;Group C (recombined TNF group) was administrated with mixture of 2.5×10~4 IUrecombinant mutant TNF and 1ml saline.MSCT scan was performed to measuretumor volume on the 7th day after intervention.The tumor growth rates and necrosisrates were measured.Tumor apoptotic indexs examined by TUNEL were comparedbetween group A and C.VEGF expression and MVD of all groups were detected byimmunohistochemistry.
Results:One week after treatment,in the recombinant mutant TNF group (group C)the tumor was significantly inhibited,tumor growth rate was lower than the group A(P＜0.05),and was similar to group B (P＞0.05).Tumor necrosis of group A wassignificantly different from group B and C,and the necrosis rate of group B and Cwas higher than group A (P＜0.05).Tumor apoptotic indexs (AI) were 1.69±0.18 ingroup A and 7.26±0.45 in group C,and there was singnificant difference betweengroup A and group C (P＜0.05).Vascular endothelial growth factor (VEGF) expression and microvessel density (MVD) of group C were singnificantly decreased(P＜0.05).
Conclusion:Recombinant mutant human TNF chemotherapy through artery to livercan inhibit tumor growth,reduce vescular growth and induce apoptosis and/or tumornecrosis.Recombinant mutant human TNF is an effective chemotherapy agent forrabbits with VX2 hepatoma.
引文
[1]马明平，胡道予，周义成．等．免 VX2肝癌模型制作及介入治疗的实验研究．放射学实践,2000，1 5(6)：284-386．
[2]郭卫平，刘燕，王执民，等，兔肝 VX2移植癌改良模型的建立．中国医学影像技术，2002，18(5)：397-399．
[3]Sotaro Sadahiro,Toshiyuki Suzuki,Kenji Ishikawa,et al.Pharmacokinetic of 5-Fluorouracil following hepatic intra-arterial infusion in a VX2 hepatic metastasis model.Jpn J Clin Onco,2003,33(8):377-381.
[4]Paul Moroz,Stephen K.Jones,Bruce N.Gray,et al.Tumor response to arterial embolization hyperthermiaand direct injection hyperthermia in a rabbit liver tumor model.J Surg Onco,2002,80(2):149-156.
[5]Radan Dzodic,Gonzalo Gomez-Abuin,Philippe Rougier,et al.Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin dministration:comparative results with splatin using a rabbit VX2 tumor model.Anti-Cancer Drugs 2004,15(6):647-650
[6]贾洪顺，全显跃．改进兔肝动脉插管术：肝血管影像研究．放射学实践，2002，17(4)：324-325．
[7]Jin Chul Paeng,Jae Min Jeong,Chang Jin Yoon,et al.Lipiodol solution of ~(188)Re-HDD as a new therapeutic agent for transhepatic arterial embolization in liver cancer:preclinical study in a rabbit liver cancer model.J Nucl Med,2003,44(12):2033-2038.
[8]吕朋华，王杰，苗毅．兔肝 VX2转移瘤模型的建立及影像学表现．南京医科大学学报(自然科学版)．2003，23(6)：545-547．
[9]曹玮，王执民，张洪新，等．兔 VX2肝癌改良模型的建立及其 DSA 影像分析．第四军医大学学报．2001，22(7)：619-622．
[10]Clare Horkan,Muneeb Ahmed,Zhengjun Liu,et al.Radiofrequency ablation:effect of pharmacologic modulation of hepatic and renal blood flow on coagulation diameter in a VX2 tumor model.J Vasc Interv Radiol,2004,15(3):269-274.
[11]Rous P,Kidd JG,Smith WE.Experiments on the cause of rabbit carcinoma derived from virusinduced papillomas.J Exp Med,1952,96(2):159.
[12]王荞，王佚，王少春，等．兔 VX2肝癌模型的建立及超声影像监测的研究．重庆医科大学学报,2003,28(5)：585-587．
[13]Michael F X Gnant,Linda A Noll,Kari R Irvine,et al.Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases.Natl Cancer Inst,1999,91 (20):1744-1750.
[14]J H Chen,Y C Lin,Y S Huang,et al.Induction of VX2 carcinoma in rabbit liver:comparison of two inoculation method.Laboratory Animals,2004,38(1):79-84.
[15]张洪新，王执民，王莉君，等．兔肝 VX2移植癌模型的病理学和影像学表现．实用放射学杂志，2002，18(7)：545-548．
[16]邵国良，周康荣，王建华，等．介入治疗实验研究中兔 VX2肝癌模型制作的改进和 CT 评价．临床放射学杂志，2000，19(10)：653-654．
[17]杨安峰．兔的解剖．北京：科学出版社．1979．102．
[1]Feng LY,Li SP,Yan YH,et al.Inhibition of HAP nanoparticle on W-256 sarcoma of rats in vivo.J Chin Biomed Engin,2001,(suppl):302-304.
[2]Liu ZS,Tang SL,Ai ZL.Effects ofhydroxyapatite nanoparticles on proliferation and apoptosis of human hepatoma BEL-7402 cells.World J Gastroenterol,2003,9 (9):1968-1971.
[3]曹献英，李世普，任卫，等．纳米羟基磷灰石的表征及其对肝癌抑制作用的研究．硅酸盐通报，2003，24(4)：21-24．
[4]齐志涛，曹献英，李世普，等．纳米磷灰灰石对肝癌细胞端粒酶基因表达的影响．武汉理工大学学报，2004，26(7)：48-50．
[5]Lin WY,Chen J ,Lin Y,et al.Implantation of VX2 carcinoma into the liver of rabbits:a comparison of three direct-injection methods.J Vet Med Sci,2002,64(7):649-652.
[6]关键，胡道予，孙振纲，等．兔 VX2肝癌 TAE 实验方法改良及影像学评价．临床放射学杂志．2006，25(3)：277-280．
[7]Itokazu M,Sugiyama T,Ohno T,et al.Development of porous apatite ceramic for local delivery of chemotherapeutic agents.J Biomed Mater Res,1998,39(4):536-538.
[8]Benghuzzi H.Long-term sustained delivery of 3'-azido-2',3'-dideoxythymidine in vivo by means of HAP and TCP delivery devices.J Biomed Sci Instrum,2000,36(2):343-348.
[9]Hideki Aoki.Effects of HAP-sol on cell growth.Report of the institute for medical and Dental Engineering,1992,26(1):15-21.
[10]冯庆玲，崔福斋，张伟．纳米羟基磷灰石/胶原骨修复材料．中国医学科学院学报，2002，24(2)：124-128．
[11]Chamberlain M,Gray B,Heggle J.Hepatic metastases——a physiological approach to treatment.Br J Surg,1983,70 (10):596-599.
[12]刘丽萍，肖雁冰，肖子文，等．家兔静脉注射羟基磷灰石纳米粒子的反应研究．卫生研究，2005，34(4)：474-476．
[1]Sadahiro S,Suzuki T,Ishikawa K,et al.Pharmacokinetic of 5-Fluorouracil following hepatic Intra-arterial infusion in a VX2 hepatic metastasis model.Jpn J Clin Onco,2002,80(2):149-156.
[2]刘华顶，五世亮，武四化，等．缓释氟尿嘧啶植入剂在大肠癌患者的药物动力学．中国新药杂志，2005，14(10)：1199．
[3]Kyotani S,Nishioka Y.The development of embolizing materials for chemoembolization therapy of hepatocellular carcinoma.Yakugaku Zasshi,2000,120(11):1173-1184.
[4]Takeuchi I,Ishida H,Inokuma S,et al.Hepatic arterial injection of degradable starch microspheres (DSM) combined with adriamycin (ADM) and mitomycin C (MMC) in patients with liver metastasis of colorectal cancer.Gan To Kagaku Ryohoi,2000,27(12):1904-1906.
[5]Lin WY,Chen J ,Lin Y,et al.Implantation of VX2 carcinoma into the liver of rabbits:a comparison of three direct-injection methods.J Vet Med Sci,2002,64(7):649-652.
[6]关键，胡道予，孙振纲，等．兔 VX2肝癌 TAE 实验方法改良及影像学评价．临床放射学杂志．2006，25(3)：277-280．
[7]Schlemmer HP,Becker M,Bachert P,et al.Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy.Cancer Res,1999,59:2363-2369.
[8]Tamura T,Fujita F,Tanimoto M,et al.Anti-tumor effect of intraperitoneal administration of cisplatin-loaded microspheres to human tumor xenografted nude mice.J Control Release,2002,80(1-3):295-307.
[9]Nijsen F,Rook D,Brandt C,et al.Targeting of liver tumour in rats by selective delivery of holmium-166 loaded microspheres:a biodistribution study.Eur J Nucl Med,2001,28(6):743-749.
[10]Chamberlain M,Gray B,Heggle J.Hepatic metastases——a physiological approach to treatment.Br J Surg,1983,70 (10):596-599.
[11]周承凯，梁惠民，李欣，等．实验兔 VX2肝肿瘤模型制作及动脉插管技术探讨．介入放射学杂志，2006，15(2)：101-104
[12]钱骏，冯敢生，Trucbenbach J，等．聚丙交酯复合乙交酯微球经肝动脉化疗栓塞术治疗肝癌的动物实验．放射学实践，2001，16(6)：381-383．
[1]Rothe J,Gehr G,Loetscher H,et al.Tumor necrosis factor structure and function.ImmunolRes,1995,11(2):81-90.
[2]Labunski S,Posem G,Ludwig S,et al.Tumor necrosis factor-alpha promoter polymorphism in erythema nodosum.Acta Derm Venereol,2001,81 (1):18-21.
[3]Lin WY,Chen J ,Lin Y,et al.Implantation of VX2 carcinoma into the liver of rabbits:a comparison of three direct-injection methods.J Vet Med Sci,2002,64(7):649-652.
[4]关键，胡道予，孙振纲，等．兔 VX2肝癌 TAE 实验方法改良及影像学评价．临床放射学杂志．2006，25(3)：277-280．
[5]Weidner N.Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors.Breast Cancer Res Treat,1995,36:169-180.
[6]Rokhlin OW,Cohen MB.Bisindolylmaleimide IX induces reversible and time-dependent tumor necrosis factor receptor family-mediated caspase activation and cell death.Cancer BiolTher,2003,2(3):266-270.
[7]Mcintosh JK,Mule J J,Travis WD,et al.Studies of effects of recombinant human tumor necrosis factor on autochthonous tumor and transpl anted normal tissue in mice.Cancer Res,2000,50(8):2463-2469.
[8] Okamoto M, Oyasu R. Transformation in vitro of a nontumo rigenic rat urothelial cell line by tumor necrosis factor-alpha. Lab Invest, 2001, 77(1): 139-143.
[9] Sorkin P, Abu-Abid S, Lev D, et al. Systemic leakage and side effects of tumor necrosis factor-a administered via isolated limb perfusion can be manipulated by flow rate adjustment[J]. Arch Surg, 2004, 130(10): 1079-1084.
[10] Burow ME, Weldon CB, Tang Y, et al. Differences in suscept ibility to tumor necrosis factor alpha induced apoptosis among MCF-7 breast cancer cell variants. Cancer Res, 2002, 58(21): 4940-4946.
[11] Reddy RM, Tsai WS, Ziauddin MF, et al. Cisplatin enhances apoptosis induced by a tumor-selective adenovirus expressing tumor necrosis ractor-related apoptosis inducing ligand. J Thorac Cardiovasc Surg, 2004, 128(6): 883-891.
[12] Sakurai A, Hara S, Okano N, et al. Rcgulatory role of metal lothioneine in NF-Kappa B activation. FEBS Lett, 1999, 455(1): 55-58.
[13] O'Reilly MS, Holmgren L, Shing Y, et al. A novel angiog enesis inhibitor that mediate the suppression of metastasis by a Lewis lung carcinoma. Cell, 1999,79(2): 185-188.
[14] Cao Y, Linden P, Shima D, etal. Proinflammatory properties of murine aortic endothelial cells exclusively expressing a non cleavable form of TNF alpha. Effect on tumor necrosis factor alpha receptor type-2. J Clin Invest, 2001, 98(2): 490-496.
[15] Vanderslice P , Munsch CL, Rachal E , et al. Angiogenesis induced by tumor necrosis factor: is mediated by alpha integrins. Angiogenesis, 1998, 2(3): 265.
[16] Nabors LB, Suswam E, Huang Y, et al. Tumor necrosis factor-alpha induces angiogenic factor up regulation in malignant glioma cells: a role for RNA stabilization. Cancer Res, 2003, 63(14): 41-81.
[17] Yang H, Li M, Chai H, et al. Expression and regulation of neuropilins and VEGF receptors by TNF-alpha in human endothelial cells. J Surg Res, 2004,122(2): 249-255.
[18] Follkman J. What is the evidence that tumors are angiogensis dependent? J Natl Cancer Inst, 1990, 82(l):4-6.
[19]Kobayashi N,Ishii M,Ueno Y,et al.Co-expression of Bcl-2 protein and vascular endothelial growth factor in hepatocellular carcinomas treated by chemoembolization.Liver,1999,19(1):25-31.
[20]An FQ,Matsuda M,Fujii H,et al.Expression of vascular endothelial growth factor in surgical specimens of hepatocellular carcinoma.J Cancer Res Clin Oncol,2000,126(2):153-160.
[21]Suzuki H,Mori M,Kawaguchi C,et al.Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of hepatocellular carcinoma.Int J Oncol,1999,14:1087-1090.
[22]Liu J,Yi J.Relationship between the changes of VEGF level and dendritic cells in peripheral blood of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization.J Huazhong Univ Sci Technolog Med Sci,2007,27(1):58-60.
[23]Poon RT,Ng IO,Lau C,et al.Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma:a prospective study.Ann Surg,2001,233:227-235.
[24]Myoung H,Hong SD,Kim YY,et al.Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma.Cancer Lett,2001,163:191-200.
[25]Folkman J.What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst,1990,82(1):4-6.
[26]DeAngelis LM.Brain tumor therapy:new horizons,new hope.Neurology,1998,50:1209-1210.
[27]Chamberlain M,Gray B,Heggle J.Hepatic metastases——a physiological approach to treatment.Br J Surg,1983,70 (10):596-599.
[28]周承凯，梁惠民，李欣，等．实验兔 VX2肝肿瘤模型制作及动脉插管技术探讨．介入放射学杂志，2006，15(2)：101-104．
[1]马旭东，王健平．纳米复合羟基磷灰石在口腔治疗中的应用．中国组织工程研究与临床康复，2008，12(1)：117-120．
[2]Domer-Reisel A,Klemm V,lrmer G,Muller E.Nano- and microstructure of short fibre reinforced and unreinforced hydmxyaptite.Biomed Tech(Berl),2002,47(1):397-400.
[3]袁媛，唐胜利，洪华，等．纳米羟基磷灰石的制备及其抗肿瘤活性的研究．中国生物医学工程学报，2005，24(1)：26-28．
[4]许艳慧．纳米羟基磷灰石的研究进展．生物医学工程国外医学：口腔医学分册，2003，30(1)：36-38．
[5]盂纯阳，安洪，蒋电明，等．纳米羟基磷灰石/聚酰胺的细胞相容性研究．中国创伤骨科杂志，2005，8(7)：749-752．
[6]温波．纳米羟基磷灰石和常规羟基磷灰石骨细胞相容性研究，华西口腔医学杂志，2004，22(6)：456-459．
[7]江捍平，王大平，阮建明，等．纳米羟基磷灰石人工骨的生物相容性研究．中国现代医学杂志，2005，23(5)：1477-1488．
[8]．袁媛，唐胜利，洪华，等．纳米羟基磷灰石的制备及其抗肿瘤活性的研究．中国生物医学工程学报，2005，24(1)：26-28．
[9]陈菲．羟基磷灰石生物医用陶瓷材料的研究与发展．中国陶瓷，2006，42：8-10．
[10]何江涛，蒋电明．纳米羟基磷灰石复合材料的研究进展．川北医学院学报，2006，26(4)：362-364．
[11]李瑞琦，张国平，任立中，等．纳米羟基磷灰石及其复合生物材料的特征及应用．中国组织工程研究与临床康复，2008，12(19)：3747-3750．
[12]李志宏，武继民，李瑞，等．纳米羟基磷灰石及其复合材料的研究进展．医疗卫生装备，2007，28(4)：30-32．
[13]Barroug A,Glimcher MJ.Hydroxyapatite crystals as a local delivery system for cisplatin:adsorption and release ofcisplatin in vitro.J Orthop Res,2002,20:274-280.
[14]Honnorat-Benabbou VC,Lebugle AA,Sallek B,et al.Stability study of tetracyclines with respect to their use in slow release systems.J Mater Sci Mater Med,2001,12:107-110.
[15]Itokazu M,Sugiyama T,Ohno T,et al.Development of porous apatite ceramic for local delivery of chemotherapeutic agents.J Biomed Mater Res,1998,39:536-538.
[16]Benghuzzi H.Long-term sustained delivery of 3'-azido-2',3'-dideoxythymidine in vivo by means of HA and TCP delivery devices.Biomed Sci Instrum,2000,36:343-348.
[17]WANG Bo,TENG Li-rong,WANG Chun-yan,et al.Protein adsorption onto nanosized hydroxyapatite particles for controlled drug release.Chem Res Chinese U,2007,23(3):254-257.
[18]Hideki Aoki.Effects of HAP-sol on cell growth.Report of the institute for medical and dental engineering,1992,26:15-21.
[19]张士成．李世普．磷灰石超微粉对癌细胞作用的初步研究．武汉工业大学学报，1996，18：5-8．
[20]曹献英，李世普，任卫，等．纳米羟基磷灰石的表征及其对肝癌抑制作用的研究．硅酸盐通报，2003,4：21-24．
[21]Kannan TP,Nik Ahmad Shah NL,Azlina A,et al.In vivo chromosome aberration test for hydroxyapetite in mice.Med J Malaysia,2004,59:115-116.
[22]唐胜利，袁媛，刘志苏，等．羟基磷灰石纳米粒子对人肝癌 BEL-7402细胞毒性评价．肝脏，2003,8：21-24．
[23]Nurse P.A long twentieth century of the cell cycle and beyond.Cell,2000,100:71-78.
[24]齐志涛，曹献英，李世普，等．纳米磷灰石对肝癌细胞端粒酶基因表达的影响．武汉理工大学学报，2004，7：26-28．
[25]付莉，冯卫，彭芝兰，等．羟基磷灰石纳米粒子对卵巢癌作用的体外实验研究．中国生物医学工程学报，2007，26：584-586．
[26]李海丰，俞光荣，王德平．纳米羟基磷灰石对骨肉瘤 U2-OS 细胞生长的影响．同济大学学报(医学版)，2005，26(1)：35-37．
[27]陈超，王慧明．纳米羟基磷灰石溶胶对人舌癌移植瘤作用．肿瘤学杂志，2006，12(4)：328-330．
[28]扈盛，闰玉华，王友法，等．HAP 纳米粒子进入癌细胞的体外实验研究．中国生物医学工程学报，2005，24(4)：482-484．
[29]Savic R,Luo L,Eisenberg A,et al.Micellar nanocontainers distribute to defined cytoplasmic organelles.Science,2003,300(25):615-618.
[30]胡军，刘志苏，唐胜利，等．羟基磷灰石纳米粒子肝动脉灌注对兔 VX2肝种植瘤生长和 bax/bcl-2蛋白表达的影响．中华实验外科杂志，2007，24(4)：438-440．
[31]Liu Zhi-Su,Tang Sheng-Li,Ai Zhong-Li,et al.Establishment of apoptotic model induced by hydroxyapatite nanoparticles in human hepatoma cell line BEL-7402.World Chin J Digest,2003,11:1357-1361.
[32]Zhang JP,Xia QH,Tian Y,et al.The role ofhydroxyapatite ultrafinepowder in DNA damage of the tumour cell lines Walker256.Practieal Journal of Cancer,1997,12(4):245-247.
[33]Feng LY,Yan YH,Chen WJ,et al.Efect of HAP-sol on Ca~(2+) concentration of W-256 sarcoma cells and morphology of cells.Chinese J Biomedical Engineering,1998,17(4):374-377.
[34]Soma CE,Dubemet C,Bentolilad,et al.Reversion of multidrug resistance by coencapsulation of doxorubicin and cyclosporine A in polyalkylcyancacrylate nanoparticles.J Biomaerials,2002,21:1-7.
[35]Schiffelers RM,Ansari A,Xu J,et al.Cancer RNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle.Nucleic Acids Res.2004,32:e149.
[36]Krylova E,Ivanov A,Orlovski V,et al.Hydroxypatite-polysaccharide granules for drug delivery.J Mater Sci Mater Med,2002,13:87-90.
[37]彭向欣，蔡湄．兔肝脏中中羟基磷灰石-阿霉素缓释剂的释放．中国临床药理学与治疗学，2002，5(1)：19．
[38]曾益新．肿瘤学(第2版)．北京：人民卫生出版社．2006．151．
[39]Tamura T,Fujita F,Tanimoto M,et al.Anti-tumor effect of intraperitoneal administration of cisplatin-loaded microspheres to human tumor xenografted nude mice.J Control Release,2002,80(1-3):295-307.
[40]Nijsen F,Rook D,Brandt C,et al.Targeting of liver tumour in rats by selective delivery of holmium-166 loaded microspheres:a biodistribution study.Eur J Nucl Med,2001,28(6):743-749.
[41]袁新彦．纳米球制剂临床应用进展．实用全科医学，2004：69．
[42]钱骏，冯敢生，Trucbenbach J，等．聚丙交酯复合乙交酯微球经肝动脉化疗栓塞术治疗肝癌的动物实验．放射学实践,2001，16(6)：381-383．
[43]林世寅，万柏坤，焦玉彦，等．铁磁性药物微球的定位栓塞及物理模拟实验研究．中国医学物理学杂志，1996，13(1)：6-9．
[2]郭卫平，刘燕，王执民，等，兔肝 VX2移植癌改良模型的建立．中国医学影像技术，2002，18(5)：397-399．
[3]Sotaro Sadahiro,Toshiyuki Suzuki,Kenji Ishikawa,et al.Pharmacokinetic of 5-Fluorouracil following hepatic intra-arterial infusion in a VX2 hepatic metastasis model.Jpn J Clin Onco,2003,33(8):377-381.
[4]Paul Moroz,Stephen K.Jones,Bruce N.Gray,et al.Tumor response to arterial embolization hyperthermiaand direct injection hyperthermia in a rabbit liver tumor model.J Surg Onco,2002,80(2):149-156.
[5]Radan Dzodic,Gonzalo Gomez-Abuin,Philippe Rougier,et al.Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin dministration:comparative results with splatin using a rabbit VX2 tumor model.Anti-Cancer Drugs 2004,15(6):647-650
[6]贾洪顺，全显跃．改进兔肝动脉插管术：肝血管影像研究．放射学实践，2002，17(4)：324-325．
[7]Jin Chul Paeng,Jae Min Jeong,Chang Jin Yoon,et al.Lipiodol solution of ~(188)Re-HDD as a new therapeutic agent for transhepatic arterial embolization in liver cancer:preclinical study in a rabbit liver cancer model.J Nucl Med,2003,44(12):2033-2038.
[8]吕朋华，王杰，苗毅．兔肝 VX2转移瘤模型的建立及影像学表现．南京医科大学学报(自然科学版)．2003，23(6)：545-547．
[9]曹玮，王执民，张洪新，等．兔 VX2肝癌改良模型的建立及其 DSA 影像分析．第四军医大学学报．2001，22(7)：619-622．
[10]Clare Horkan,Muneeb Ahmed,Zhengjun Liu,et al.Radiofrequency ablation:effect of pharmacologic modulation of hepatic and renal blood flow on coagulation diameter in a VX2 tumor model.J Vasc Interv Radiol,2004,15(3):269-274.
[11]Rous P,Kidd JG,Smith WE.Experiments on the cause of rabbit carcinoma derived from virusinduced papillomas.J Exp Med,1952,96(2):159.
[12]王荞，王佚，王少春，等．兔 VX2肝癌模型的建立及超声影像监测的研究．重庆医科大学学报,2003,28(5)：585-587．
[13]Michael F X Gnant,Linda A Noll,Kari R Irvine,et al.Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases.Natl Cancer Inst,1999,91 (20):1744-1750.
[14]J H Chen,Y C Lin,Y S Huang,et al.Induction of VX2 carcinoma in rabbit liver:comparison of two inoculation method.Laboratory Animals,2004,38(1):79-84.
[15]张洪新，王执民，王莉君，等．兔肝 VX2移植癌模型的病理学和影像学表现．实用放射学杂志，2002，18(7)：545-548．
[16]邵国良，周康荣，王建华，等．介入治疗实验研究中兔 VX2肝癌模型制作的改进和 CT 评价．临床放射学杂志，2000，19(10)：653-654．
[17]杨安峰．兔的解剖．北京：科学出版社．1979．102．
[1]Feng LY,Li SP,Yan YH,et al.Inhibition of HAP nanoparticle on W-256 sarcoma of rats in vivo.J Chin Biomed Engin,2001,(suppl):302-304.
[2]Liu ZS,Tang SL,Ai ZL.Effects ofhydroxyapatite nanoparticles on proliferation and apoptosis of human hepatoma BEL-7402 cells.World J Gastroenterol,2003,9 (9):1968-1971.
[3]曹献英，李世普，任卫，等．纳米羟基磷灰石的表征及其对肝癌抑制作用的研究．硅酸盐通报，2003，24(4)：21-24．
[4]齐志涛，曹献英，李世普，等．纳米磷灰灰石对肝癌细胞端粒酶基因表达的影响．武汉理工大学学报，2004，26(7)：48-50．
[5]Lin WY,Chen J ,Lin Y,et al.Implantation of VX2 carcinoma into the liver of rabbits:a comparison of three direct-injection methods.J Vet Med Sci,2002,64(7):649-652.
[6]关键，胡道予，孙振纲，等．兔 VX2肝癌 TAE 实验方法改良及影像学评价．临床放射学杂志．2006，25(3)：277-280．
[7]Itokazu M,Sugiyama T,Ohno T,et al.Development of porous apatite ceramic for local delivery of chemotherapeutic agents.J Biomed Mater Res,1998,39(4):536-538.
[8]Benghuzzi H.Long-term sustained delivery of 3'-azido-2',3'-dideoxythymidine in vivo by means of HAP and TCP delivery devices.J Biomed Sci Instrum,2000,36(2):343-348.
[9]Hideki Aoki.Effects of HAP-sol on cell growth.Report of the institute for medical and Dental Engineering,1992,26(1):15-21.
[10]冯庆玲，崔福斋，张伟．纳米羟基磷灰石/胶原骨修复材料．中国医学科学院学报，2002，24(2)：124-128．
[11]Chamberlain M,Gray B,Heggle J.Hepatic metastases——a physiological approach to treatment.Br J Surg,1983,70 (10):596-599.
[12]刘丽萍，肖雁冰，肖子文，等．家兔静脉注射羟基磷灰石纳米粒子的反应研究．卫生研究，2005，34(4)：474-476．
[1]Sadahiro S,Suzuki T,Ishikawa K,et al.Pharmacokinetic of 5-Fluorouracil following hepatic Intra-arterial infusion in a VX2 hepatic metastasis model.Jpn J Clin Onco,2002,80(2):149-156.
[2]刘华顶，五世亮，武四化，等．缓释氟尿嘧啶植入剂在大肠癌患者的药物动力学．中国新药杂志，2005，14(10)：1199．
[3]Kyotani S,Nishioka Y.The development of embolizing materials for chemoembolization therapy of hepatocellular carcinoma.Yakugaku Zasshi,2000,120(11):1173-1184.
[4]Takeuchi I,Ishida H,Inokuma S,et al.Hepatic arterial injection of degradable starch microspheres (DSM) combined with adriamycin (ADM) and mitomycin C (MMC) in patients with liver metastasis of colorectal cancer.Gan To Kagaku Ryohoi,2000,27(12):1904-1906.
[5]Lin WY,Chen J ,Lin Y,et al.Implantation of VX2 carcinoma into the liver of rabbits:a comparison of three direct-injection methods.J Vet Med Sci,2002,64(7):649-652.
[6]关键，胡道予，孙振纲，等．兔 VX2肝癌 TAE 实验方法改良及影像学评价．临床放射学杂志．2006，25(3)：277-280．
[7]Schlemmer HP,Becker M,Bachert P,et al.Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy.Cancer Res,1999,59:2363-2369.
[8]Tamura T,Fujita F,Tanimoto M,et al.Anti-tumor effect of intraperitoneal administration of cisplatin-loaded microspheres to human tumor xenografted nude mice.J Control Release,2002,80(1-3):295-307.
[9]Nijsen F,Rook D,Brandt C,et al.Targeting of liver tumour in rats by selective delivery of holmium-166 loaded microspheres:a biodistribution study.Eur J Nucl Med,2001,28(6):743-749.
[10]Chamberlain M,Gray B,Heggle J.Hepatic metastases——a physiological approach to treatment.Br J Surg,1983,70 (10):596-599.
[11]周承凯，梁惠民，李欣，等．实验兔 VX2肝肿瘤模型制作及动脉插管技术探讨．介入放射学杂志，2006，15(2)：101-104
[12]钱骏，冯敢生，Trucbenbach J，等．聚丙交酯复合乙交酯微球经肝动脉化疗栓塞术治疗肝癌的动物实验．放射学实践，2001，16(6)：381-383．
[1]Rothe J,Gehr G,Loetscher H,et al.Tumor necrosis factor structure and function.ImmunolRes,1995,11(2):81-90.
[2]Labunski S,Posem G,Ludwig S,et al.Tumor necrosis factor-alpha promoter polymorphism in erythema nodosum.Acta Derm Venereol,2001,81 (1):18-21.
[3]Lin WY,Chen J ,Lin Y,et al.Implantation of VX2 carcinoma into the liver of rabbits:a comparison of three direct-injection methods.J Vet Med Sci,2002,64(7):649-652.
[4]关键，胡道予，孙振纲，等．兔 VX2肝癌 TAE 实验方法改良及影像学评价．临床放射学杂志．2006，25(3)：277-280．
[5]Weidner N.Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors.Breast Cancer Res Treat,1995,36:169-180.
[6]Rokhlin OW,Cohen MB.Bisindolylmaleimide IX induces reversible and time-dependent tumor necrosis factor receptor family-mediated caspase activation and cell death.Cancer BiolTher,2003,2(3):266-270.
[7]Mcintosh JK,Mule J J,Travis WD,et al.Studies of effects of recombinant human tumor necrosis factor on autochthonous tumor and transpl anted normal tissue in mice.Cancer Res,2000,50(8):2463-2469.
[8] Okamoto M, Oyasu R. Transformation in vitro of a nontumo rigenic rat urothelial cell line by tumor necrosis factor-alpha. Lab Invest, 2001, 77(1): 139-143.
[9] Sorkin P, Abu-Abid S, Lev D, et al. Systemic leakage and side effects of tumor necrosis factor-a administered via isolated limb perfusion can be manipulated by flow rate adjustment[J]. Arch Surg, 2004, 130(10): 1079-1084.
[10] Burow ME, Weldon CB, Tang Y, et al. Differences in suscept ibility to tumor necrosis factor alpha induced apoptosis among MCF-7 breast cancer cell variants. Cancer Res, 2002, 58(21): 4940-4946.
[11] Reddy RM, Tsai WS, Ziauddin MF, et al. Cisplatin enhances apoptosis induced by a tumor-selective adenovirus expressing tumor necrosis ractor-related apoptosis inducing ligand. J Thorac Cardiovasc Surg, 2004, 128(6): 883-891.
[12] Sakurai A, Hara S, Okano N, et al. Rcgulatory role of metal lothioneine in NF-Kappa B activation. FEBS Lett, 1999, 455(1): 55-58.
[13] O'Reilly MS, Holmgren L, Shing Y, et al. A novel angiog enesis inhibitor that mediate the suppression of metastasis by a Lewis lung carcinoma. Cell, 1999,79(2): 185-188.
[14] Cao Y, Linden P, Shima D, etal. Proinflammatory properties of murine aortic endothelial cells exclusively expressing a non cleavable form of TNF alpha. Effect on tumor necrosis factor alpha receptor type-2. J Clin Invest, 2001, 98(2): 490-496.
[15] Vanderslice P , Munsch CL, Rachal E , et al. Angiogenesis induced by tumor necrosis factor: is mediated by alpha integrins. Angiogenesis, 1998, 2(3): 265.
[16] Nabors LB, Suswam E, Huang Y, et al. Tumor necrosis factor-alpha induces angiogenic factor up regulation in malignant glioma cells: a role for RNA stabilization. Cancer Res, 2003, 63(14): 41-81.
[17] Yang H, Li M, Chai H, et al. Expression and regulation of neuropilins and VEGF receptors by TNF-alpha in human endothelial cells. J Surg Res, 2004,122(2): 249-255.
[18] Follkman J. What is the evidence that tumors are angiogensis dependent? J Natl Cancer Inst, 1990, 82(l):4-6.
[19]Kobayashi N,Ishii M,Ueno Y,et al.Co-expression of Bcl-2 protein and vascular endothelial growth factor in hepatocellular carcinomas treated by chemoembolization.Liver,1999,19(1):25-31.
[20]An FQ,Matsuda M,Fujii H,et al.Expression of vascular endothelial growth factor in surgical specimens of hepatocellular carcinoma.J Cancer Res Clin Oncol,2000,126(2):153-160.
[21]Suzuki H,Mori M,Kawaguchi C,et al.Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of hepatocellular carcinoma.Int J Oncol,1999,14:1087-1090.
[22]Liu J,Yi J.Relationship between the changes of VEGF level and dendritic cells in peripheral blood of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization.J Huazhong Univ Sci Technolog Med Sci,2007,27(1):58-60.
[23]Poon RT,Ng IO,Lau C,et al.Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma:a prospective study.Ann Surg,2001,233:227-235.
[24]Myoung H,Hong SD,Kim YY,et al.Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma.Cancer Lett,2001,163:191-200.
[25]Folkman J.What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst,1990,82(1):4-6.
[26]DeAngelis LM.Brain tumor therapy:new horizons,new hope.Neurology,1998,50:1209-1210.
[27]Chamberlain M,Gray B,Heggle J.Hepatic metastases——a physiological approach to treatment.Br J Surg,1983,70 (10):596-599.
[28]周承凯，梁惠民，李欣，等．实验兔 VX2肝肿瘤模型制作及动脉插管技术探讨．介入放射学杂志，2006，15(2)：101-104．
[1]马旭东，王健平．纳米复合羟基磷灰石在口腔治疗中的应用．中国组织工程研究与临床康复，2008，12(1)：117-120．
[2]Domer-Reisel A,Klemm V,lrmer G,Muller E.Nano- and microstructure of short fibre reinforced and unreinforced hydmxyaptite.Biomed Tech(Berl),2002,47(1):397-400.
[3]袁媛，唐胜利，洪华，等．纳米羟基磷灰石的制备及其抗肿瘤活性的研究．中国生物医学工程学报，2005，24(1)：26-28．
[4]许艳慧．纳米羟基磷灰石的研究进展．生物医学工程国外医学：口腔医学分册，2003，30(1)：36-38．
[5]盂纯阳，安洪，蒋电明，等．纳米羟基磷灰石/聚酰胺的细胞相容性研究．中国创伤骨科杂志，2005，8(7)：749-752．
[6]温波．纳米羟基磷灰石和常规羟基磷灰石骨细胞相容性研究，华西口腔医学杂志，2004，22(6)：456-459．
[7]江捍平，王大平，阮建明，等．纳米羟基磷灰石人工骨的生物相容性研究．中国现代医学杂志，2005，23(5)：1477-1488．
[8]．袁媛，唐胜利，洪华，等．纳米羟基磷灰石的制备及其抗肿瘤活性的研究．中国生物医学工程学报，2005，24(1)：26-28．
[9]陈菲．羟基磷灰石生物医用陶瓷材料的研究与发展．中国陶瓷，2006，42：8-10．
[10]何江涛，蒋电明．纳米羟基磷灰石复合材料的研究进展．川北医学院学报，2006，26(4)：362-364．
[11]李瑞琦，张国平，任立中，等．纳米羟基磷灰石及其复合生物材料的特征及应用．中国组织工程研究与临床康复，2008，12(19)：3747-3750．
[12]李志宏，武继民，李瑞，等．纳米羟基磷灰石及其复合材料的研究进展．医疗卫生装备，2007，28(4)：30-32．
[13]Barroug A,Glimcher MJ.Hydroxyapatite crystals as a local delivery system for cisplatin:adsorption and release ofcisplatin in vitro.J Orthop Res,2002,20:274-280.
[14]Honnorat-Benabbou VC,Lebugle AA,Sallek B,et al.Stability study of tetracyclines with respect to their use in slow release systems.J Mater Sci Mater Med,2001,12:107-110.
[15]Itokazu M,Sugiyama T,Ohno T,et al.Development of porous apatite ceramic for local delivery of chemotherapeutic agents.J Biomed Mater Res,1998,39:536-538.
[16]Benghuzzi H.Long-term sustained delivery of 3'-azido-2',3'-dideoxythymidine in vivo by means of HA and TCP delivery devices.Biomed Sci Instrum,2000,36:343-348.
[17]WANG Bo,TENG Li-rong,WANG Chun-yan,et al.Protein adsorption onto nanosized hydroxyapatite particles for controlled drug release.Chem Res Chinese U,2007,23(3):254-257.
[18]Hideki Aoki.Effects of HAP-sol on cell growth.Report of the institute for medical and dental engineering,1992,26:15-21.
[19]张士成．李世普．磷灰石超微粉对癌细胞作用的初步研究．武汉工业大学学报，1996，18：5-8．
[20]曹献英，李世普，任卫，等．纳米羟基磷灰石的表征及其对肝癌抑制作用的研究．硅酸盐通报，2003,4：21-24．
[21]Kannan TP,Nik Ahmad Shah NL,Azlina A,et al.In vivo chromosome aberration test for hydroxyapetite in mice.Med J Malaysia,2004,59:115-116.
[22]唐胜利，袁媛，刘志苏，等．羟基磷灰石纳米粒子对人肝癌 BEL-7402细胞毒性评价．肝脏，2003,8：21-24．
[23]Nurse P.A long twentieth century of the cell cycle and beyond.Cell,2000,100:71-78.
[24]齐志涛，曹献英，李世普，等．纳米磷灰石对肝癌细胞端粒酶基因表达的影响．武汉理工大学学报，2004，7：26-28．
[25]付莉，冯卫，彭芝兰，等．羟基磷灰石纳米粒子对卵巢癌作用的体外实验研究．中国生物医学工程学报，2007，26：584-586．
[26]李海丰，俞光荣，王德平．纳米羟基磷灰石对骨肉瘤 U2-OS 细胞生长的影响．同济大学学报(医学版)，2005，26(1)：35-37．
[27]陈超，王慧明．纳米羟基磷灰石溶胶对人舌癌移植瘤作用．肿瘤学杂志，2006，12(4)：328-330．
[28]扈盛，闰玉华，王友法，等．HAP 纳米粒子进入癌细胞的体外实验研究．中国生物医学工程学报，2005，24(4)：482-484．
[29]Savic R,Luo L,Eisenberg A,et al.Micellar nanocontainers distribute to defined cytoplasmic organelles.Science,2003,300(25):615-618.
[30]胡军，刘志苏，唐胜利，等．羟基磷灰石纳米粒子肝动脉灌注对兔 VX2肝种植瘤生长和 bax/bcl-2蛋白表达的影响．中华实验外科杂志，2007，24(4)：438-440．
[31]Liu Zhi-Su,Tang Sheng-Li,Ai Zhong-Li,et al.Establishment of apoptotic model induced by hydroxyapatite nanoparticles in human hepatoma cell line BEL-7402.World Chin J Digest,2003,11:1357-1361.
[32]Zhang JP,Xia QH,Tian Y,et al.The role ofhydroxyapatite ultrafinepowder in DNA damage of the tumour cell lines Walker256.Practieal Journal of Cancer,1997,12(4):245-247.
[33]Feng LY,Yan YH,Chen WJ,et al.Efect of HAP-sol on Ca~(2+) concentration of W-256 sarcoma cells and morphology of cells.Chinese J Biomedical Engineering,1998,17(4):374-377.
[34]Soma CE,Dubemet C,Bentolilad,et al.Reversion of multidrug resistance by coencapsulation of doxorubicin and cyclosporine A in polyalkylcyancacrylate nanoparticles.J Biomaerials,2002,21:1-7.
[35]Schiffelers RM,Ansari A,Xu J,et al.Cancer RNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle.Nucleic Acids Res.2004,32:e149.
[36]Krylova E,Ivanov A,Orlovski V,et al.Hydroxypatite-polysaccharide granules for drug delivery.J Mater Sci Mater Med,2002,13:87-90.
[37]彭向欣，蔡湄．兔肝脏中中羟基磷灰石-阿霉素缓释剂的释放．中国临床药理学与治疗学，2002，5(1)：19．
[38]曾益新．肿瘤学(第2版)．北京：人民卫生出版社．2006．151．
[39]Tamura T,Fujita F,Tanimoto M,et al.Anti-tumor effect of intraperitoneal administration of cisplatin-loaded microspheres to human tumor xenografted nude mice.J Control Release,2002,80(1-3):295-307.
[40]Nijsen F,Rook D,Brandt C,et al.Targeting of liver tumour in rats by selective delivery of holmium-166 loaded microspheres:a biodistribution study.Eur J Nucl Med,2001,28(6):743-749.
[41]袁新彦．纳米球制剂临床应用进展．实用全科医学，2004：69．
[42]钱骏，冯敢生，Trucbenbach J，等．聚丙交酯复合乙交酯微球经肝动脉化疗栓塞术治疗肝癌的动物实验．放射学实践,2001，16(6)：381-383．
[43]林世寅，万柏坤，焦玉彦，等．铁磁性药物微球的定位栓塞及物理模拟实验研究．中国医学物理学杂志，1996，13(1)：6-9．